RADAR-CNS is a European research consortium dedicated to developing passive, digital detection of relapse in depression, multiple sclerosis and epilepsy. I reported into Prof Matthew Hotopf who leads the program, researching and defining the smartphone and wearable device sensors with a team of leading academics from across the consortium.
RADAR-CNS is a major new research programme which is developing new ways of monitoring major depressive disorder, epilepsy, and multiple sclerosis using wearable devices and smartphone technology. RADAR-CNS aims to improve patients’ quality of life, and potentially to change how these and other chronic disorders are treated.
RADAR-CNS is jointly led by King’s College London and Janssen Pharmaceutica NV, funded by the Innovative Medicines Initiative (a Public Private Partnership established between the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Union) and includes 23 organisations from across Europe and the US. It brings together experts from diverse fields including clinical research, engineering, computer science, information technology, data analytics and health services.